JP7698715B2 - Ｃｒｉｓｐｒ ｖ型系のためのｄｎａ含有ポリヌクレオチドおよびガイド、ならびにこれらを製造する方法および使用する方法 - Google Patents

Ｃｒｉｓｐｒ ｖ型系のためのｄｎａ含有ポリヌクレオチドおよびガイド、ならびにこれらを製造する方法および使用する方法 Download PDF

Info

Publication number
JP7698715B2
JP7698715B2 JP2023523535A JP2023523535A JP7698715B2 JP 7698715 B2 JP7698715 B2 JP 7698715B2 JP 2023523535 A JP2023523535 A JP 2023523535A JP 2023523535 A JP2023523535 A JP 2023523535A JP 7698715 B2 JP7698715 B2 JP 7698715B2
Authority
JP
Japan
Prior art keywords
sequence
target
cells
nucleic acid
cas12
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023523535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546158A (ja
JP2023546158A5 (https=
Inventor
ポール・ダニエル・ドノヒュー
Original Assignee
カリブー・バイオサイエンシーズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カリブー・バイオサイエンシーズ・インコーポレイテッド filed Critical カリブー・バイオサイエンシーズ・インコーポレイテッド
Publication of JP2023546158A publication Critical patent/JP2023546158A/ja
Publication of JP2023546158A5 publication Critical patent/JP2023546158A5/ja
Application granted granted Critical
Publication of JP7698715B2 publication Critical patent/JP7698715B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3531—Hydrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023523535A 2020-10-19 2021-10-18 Ｃｒｉｓｐｒ ｖ型系のためのｄｎａ含有ポリヌクレオチドおよびガイド、ならびにこれらを製造する方法および使用する方法 Active JP7698715B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063093459P 2020-10-19 2020-10-19
US63/093,459 2020-10-19
US202063127648P 2020-12-18 2020-12-18
US63/127,648 2020-12-18
US202163229870P 2021-08-05 2021-08-05
US63/229,870 2021-08-05
PCT/US2021/055394 WO2022086846A2 (en) 2020-10-19 2021-10-18 Dna-containing polynucleotides and guides for crispr type v systems, and methods of making and using the same

Publications (3)

Publication Number Publication Date
JP2023546158A JP2023546158A (ja) 2023-11-01
JP2023546158A5 JP2023546158A5 (https=) 2023-11-09
JP7698715B2 true JP7698715B2 (ja) 2025-06-25

Family

ID=78819995

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023523535A Active JP7698715B2 (ja) 2020-10-19 2021-10-18 Ｃｒｉｓｐｒ ｖ型系のためのｄｎａ含有ポリヌクレオチドおよびガイド、ならびにこれらを製造する方法および使用する方法

Country Status (9)

Country Link
US (1) US20250027078A1 (https=)
EP (1) EP4229198A2 (https=)
JP (1) JP7698715B2 (https=)
KR (1) KR20230090337A (https=)
AU (1) AU2021364314C1 (https=)
CA (1) CA3198905A1 (https=)
IL (1) IL302220A (https=)
MX (1) MX2023004505A (https=)
WO (1) WO2022086846A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110494559B (zh) * 2017-03-28 2023-10-31 味之素株式会社 不分化地维持用培养基添加剂
EP4508211A2 (en) * 2022-04-13 2025-02-19 Caribou Biosciences, Inc. Therapeutic applications of crispr type v systems
WO2023225035A2 (en) * 2022-05-16 2023-11-23 Artisan Development Labs, Inc. Compositions and methods for engineering cells
EP4504764A1 (en) 2022-05-26 2025-02-12 Caribou Biosciences, Inc. Cytokine-receptor fusions for immune cell stimulation
WO2024046307A1 (zh) * 2022-08-29 2024-03-07 北京迅识科技有限公司 一种突变的v型crispr酶及其应用
AU2023353989A1 (en) 2022-09-30 2025-02-27 Caribou Biosciences, Inc. Anti-ror1 chimeric antigen receptors (cars), cells expressing the cars and related methods
WO2024102434A1 (en) 2022-11-10 2024-05-16 Senda Biosciences, Inc. Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
EP4584283A1 (en) 2022-11-14 2025-07-16 Caribou Biosciences, Inc. Anti-cll-1 chimeric antigen receptors, engineered cells and related methods
AU2024236558A1 (en) 2023-03-15 2025-10-09 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
EP4704886A1 (en) * 2023-05-01 2026-03-11 Caribou Biosciences, Inc. Treatment of autoimmune diseases with bcma-targeting engineered immune cells
WO2025006880A1 (en) 2023-06-29 2025-01-02 Caribou Biosciences, Inc. Diagnostic and therapeutic methods for use with ror1 antagonists
WO2025024679A1 (en) * 2023-07-26 2025-01-30 Caribou Biosciences, Inc. In vitro validation methods for car-t cell therapies
AU2024335327A1 (en) 2023-09-01 2026-03-26 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025117745A1 (en) 2023-12-01 2025-06-05 Caribou Biosciences, Inc. Methods and compositions for improving precision of endonuclease-mediated genome editing
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025231432A1 (en) * 2024-05-03 2025-11-06 Caribou Biosciences, Inc. In vivo gene editing with crispr systems
WO2026024468A1 (en) 2024-07-26 2026-01-29 Caribou Biosciences, Inc. Modular linked chimeric antigen receptors
CN119881333B (zh) * 2025-01-27 2025-11-28 上海市肿瘤研究所 一种dna纳米花级联crispr系统的蛋白标志物检测平台及其构建方法和应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017190663A1 (zh) 2016-05-04 2017-11-09 广州广电运通金融电子股份有限公司 一种基于Linux的注册表服务系统、方法及金融自助设备
WO2017218185A1 (en) 2016-06-14 2017-12-21 Pioneer Hi-Bred International, Inc. Use of cpf1 endonuclease for plant genome modifications
WO2018009822A1 (en) 2016-07-08 2018-01-11 Ohio State Innovation Foundation Modified nucleic acids, hybrid guide rnas, and uses thereof
JP2018503386A (ja) 2015-01-28 2018-02-08 パイオニア ハイ−ブレッド インターナショナル， インコーポレイテッド Ｃｒｉｓｐｒハイブリッドｄｎａ／ｒｎａポリヌクレオチドおよび使用方法
JP2019507599A (ja) 2016-03-04 2019-03-22 エディタス・メディシン、インコーポレイテッド がん免疫療法のためのｃｒｉｓｐｒ−ｃｐｆ１関連方法、組成物および構成要素
CN110616189A (zh) 2018-06-20 2019-12-27 西安桑尼赛尔生物医药有限公司 通用型靶向cd19抗原嵌合受体t细胞的制备及其应用
WO2020007593A1 (en) 2018-07-02 2020-01-09 Cellectis Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
JP2020503017A (ja) 2016-12-28 2020-01-30 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 修飾ｃｒｉｓｐｒ ｒｎａ及びその使用
WO2020168300A1 (en) 2019-02-15 2020-08-20 Editas Medicine, Inc. Modified natural killer (nk) cells for immunotherapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017190664A1 (zh) * 2016-05-05 2017-11-09 苏州吉玛基因股份有限公司 化学合成的crRNA和修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018503386A (ja) 2015-01-28 2018-02-08 パイオニア ハイ−ブレッド インターナショナル， インコーポレイテッド Ｃｒｉｓｐｒハイブリッドｄｎａ／ｒｎａポリヌクレオチドおよび使用方法
JP2019507599A (ja) 2016-03-04 2019-03-22 エディタス・メディシン、インコーポレイテッド がん免疫療法のためのｃｒｉｓｐｒ−ｃｐｆ１関連方法、組成物および構成要素
WO2017190663A1 (zh) 2016-05-04 2017-11-09 广州广电运通金融电子股份有限公司 一种基于Linux的注册表服务系统、方法及金融自助设备
WO2017218185A1 (en) 2016-06-14 2017-12-21 Pioneer Hi-Bred International, Inc. Use of cpf1 endonuclease for plant genome modifications
WO2018009822A1 (en) 2016-07-08 2018-01-11 Ohio State Innovation Foundation Modified nucleic acids, hybrid guide rnas, and uses thereof
JP2020503017A (ja) 2016-12-28 2020-01-30 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 修飾ｃｒｉｓｐｒ ｒｎａ及びその使用
CN110616189A (zh) 2018-06-20 2019-12-27 西安桑尼赛尔生物医药有限公司 通用型靶向cd19抗原嵌合受体t细胞的制备及其应用
WO2020007593A1 (en) 2018-07-02 2020-01-09 Cellectis Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
WO2020168300A1 (en) 2019-02-15 2020-08-20 Editas Medicine, Inc. Modified natural killer (nk) cells for immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nucleic Acids Research，2020年，Vol.48, No.15，pp.8601-8616

Also Published As

Publication number Publication date
WO2022086846A2 (en) 2022-04-28
KR20230090337A (ko) 2023-06-21
JP2023546158A (ja) 2023-11-01
EP4229198A2 (en) 2023-08-23
AU2021364314A1 (en) 2023-03-16
WO2022086846A3 (en) 2022-07-21
MX2023004505A (es) 2023-05-10
AU2021364314C1 (en) 2025-02-20
IL302220A (en) 2023-06-01
WO2022086846A9 (en) 2023-06-15
CA3198905A1 (en) 2022-04-28
AU2021364314B2 (en) 2024-11-21
US20250027078A1 (en) 2025-01-23

Similar Documents

Publication Publication Date Title
JP7698715B2 (ja) Ｃｒｉｓｐｒ ｖ型系のためのｄｎａ含有ポリヌクレオチドおよびガイド、ならびにこれらを製造する方法および使用する方法
JP7224318B2 (ja) 養子細胞療法用の操作された細胞
AU2018358250B2 (en) Methods, compositions and components for CRISPR-CAS9 editing of TGFBR2 in T cells for immunotherapy
US20220348929A1 (en) Crispr abasic restricted nucleotides and crispr accuracy via analogs
CN106103475B (zh) 产生同种异体移植相容的t细胞的方法
CN110944652A (zh) T细胞抗原靶向的嵌合抗原受体(car)以及在细胞疗法中的用途
KR20230042283A (ko) 재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법
JP7754722B2 (ja) 改変されたｃｄ２４７遺伝子座からキメラ受容体を発現する細胞、関連ポリヌクレオチド、および方法
JP2023538303A (ja) 所望の表現型を有するｃａｒ ｔ細胞の操作および選択のための組成物および方法
KR20200079312A (ko) 면역요법을 위한 t 세포 내 cblb의 crispr-cas9 편집 방법, 조성물 및 성분
US20230398148A1 (en) Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
CN116507722A (zh) 用于crispr v型系统的含有dna的多核苷酸和引导物及制备和使用其的方法
RU2832314C1 (ru) Днк-содержащие полинуклеотиды и руководящие последовательности для систем crispr типа v и способы их получения и применения
HK40113333A (en) Crispr abasic restricted nucleotides and crispr accuracy via analogs
RU2835579C2 (ru) Способы получения клеток, экспрессирующих рекомбинантный рецептор, и родственные композиции
KR20260053029A (ko) 생체내 반감기가 연장된 조작된 t 세포 및 그 제조 방법
WO2025029606A1 (en) Modified immune effector cells with improved resistance to natural killer cell-mediated allorejection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250507

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250613

R150 Certificate of patent or registration of utility model

Ref document number: 7698715

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150